615. Is Ozempic as Magical as It Sounds?

In a wide-ranging conversation with Ezekiel Emanuel, the policymaking physician and medical gadfly, we discuss the massive effects of GLP-1 drugs like Ozempic, Wegovy, and Mounjaro. We also talk about the state of cancer care, mysteries in the gut microbiome, flaws in the U.S. healthcare system — and what a second Trump term means for healthcare policy. SOURCES: Ezekiel Emanuel , vice provost for Global Initiatives, co-director of the Health Transformation Institute, and professor at the University of Pennsylvania Perelman School of Medicine. RESOURCES: " Obesity Drugs Would Be Covered by Medicare and Medicaid Under Biden Proposal ," by Margot Sanger-Katz ( The New York Times, 2024). " International Coverage of GLP-1 Receptor Agonists: A Review and Ethical Analysis of Discordant Approaches ," by Johan L. Dellgren, and Govind Persad, and Ezekiel J. Emanuel ( The Lancet, 2024). The Coming Wave: Technology, Power, and the Twenty-first Century's Greatest Dilemma , by Mustafa Suleyman (2023). " The Significance of Blockbusters in the Pharmaceutical Industry ," by Alexander Schuhmacher, Markus Hinder, Nikolaj Boger, Dominik Hartl, and Oliver Gassmann ( Nature Reviews Drug Discovery, 2022…